The brain somatostatin (somatotropin release-inhibiting factor; SRIF) receptor was purified by affinity chromatographic techniques. A protein of 60 kDa could be purified from rat brain. 
SRIF induces its physiological actions by interacting with cell-surface receptors. These receptors have been mainly characterized by ligand-binding techniques (1, 6) . SRIF receptors have the same distribution in brain as SRIF, and the pharmacological properties of these SRIF receptors in brain are similar in general to those in other tissues responsive to the peptide (1) .
SRIF has been shown to induce its physiological effects through multiple cellular mechanisms (1, 7, 8) . In addition to inhibiting adenylate cyclase activity (9, 10) , SRIF also modifies ionic conductance through different voltage-gated channels, including both potassium and calcium channels (11) (12) (13) (14) . Recently, several investigators (15) (16) (17) have proposed that SRIF receptor subtypes exist in the brain. The existence of receptor subtypes may help to explain the diverse actions of SRIF in brain. They also may aid in revealing different physiological actions of SRIF and its precursor somatostatin 28, which may be a neurotransmitter distinct from SRIF (18) .
Purification of the brain SRIF receptor will allow for the structural analysis of this membrane-bound protein. Identification of the biochemical properties of the SRIF receptor would help to establish how the receptor couples to other membrane components, such as the adenylate cyclase complex and ionic conductance channels. Such information also will be necessary to determine whether SRIF receptor subtypes truly exist. Presently there is no information on the physical properties of brain SRIF receptors, and no investigator has been able to solubilize or purify the SRIF receptor. In the present study, we present a procedure for the purification of brain SRIF receptors by affinity chromatography.
METHODS
Materials. [D-Trp8]SRIF, somatostatin 28, and somatostatin 28-(1-14) were obtained from Bachem. SMS 201-996 was a gift from Sandoz Pharmaceutical. N-Hydroxysuccinimidyl 4-azidobenzoate (HSAB) was obtained from Pierce. 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), and soybean phosphatidylcholine (type II-S) were obtained from Sigma. Affi-Gel 10 and silver staining reagents were from Bio-Rad. The iodination of CGP 239% was as described (6) .
Tissue Culture. AtT-20 cells were subcultured as described (17) . The cells are plated on 75-cm2 tissue culture flasks and grown in the presence of Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum. The cells are used 4-5 days after subculturing, at which time they are 60-80% confluent. CHO cells, obtained from the University of Pennsylvania Cell Center, were grown in DMEM with 10% fetal calf serum in a similar manner as the AtT-20 cells.
Solubilization and Purification of the SRIF Receptor. For the solubilization of the SRIF receptor, rat brains minus the cerebellum were homogenized in 10 vol of 50 mM Tris HCl (pH 7.4) containing 1 mM EGTA; 5 mM MgCl2; 10 ,ug of leupeptin, 10 pug of pepstatin, 200 tkg of bacitracin, and 0.5 ,ug of aprotinin per ml; and 100 mM phenylmethylsulfonyl fluoride (buffer I). The homogenates were centrifuged at 600 x g for 5 min at 40C, and the supernatants were saved. The pellets were resuspended in 10 vol of buffer I and recentrifuged at 600 x g for 5 min. The two supernatants were combined and centrifuged at 45,000 x g for 30 min at 40C. The pellets were resuspended and centrifuged again at 45,000 x g. The resulting pellets were solubilized in buffer I containing 10 mM CHAPS, 0.65 mg of crude soybean phospholipid per ml, and 20% (vol/vol) glycerol (buffer II). The pellets were then homogenized in buffer II, stirred on ice for 60 min, and centrifuged for 60 min at 100,000 x g. The solubilized protein was removed and used immediately. For the solubilization of AtT-20 or CHO cell membranes, similar procedures as described above were used except that 30-50 million AtT-20 cells or CHO cells were used.
In the preparation of the [D-Trp8]SRIF affinity column, 0.4 ml of Affi-Gel 10 was washed as described by the manufac- SDS/PAGE. Gel electrophoresis was performed as described by Laemmli (19) with 1.5-mm thick slab gels containing 10% or 15% acrylamide. After electrophoresis the gels were fixed in 3% trichloroacetic acid for 2 hr and dried by using a Bio-Rad model 483 slab dryer. Autoradiograms were obtained from the dried gels after exposure to Kodak XAR-5 film with a Dupont Cronex Lightning Plus intensifying screen at -700C.
Photoafflinity Labeling of SRIF Receptors with 12sI-Labeled CGP 23996 (125IICGP 23996). For these studies, brains minus cerebellum were removed from 200-to 250-g male SpragueDawley rats immediately after decapitation and were homogenized in 10 vol of 50 mM Tris HCl (pH 7.4) with a Polytron (Brinkman; setting 2 for 30 sec). For studies with AtT-20 or CHO cells, the cells were harvested by removing the growth medium and detaching the cells from the flask with 50 mM Tris HCl (pH 7.4). The cells then were homogenized with a Polytron. Brain and tumor cell membranes were prepared by procedures previously described (17) . Briefly, homogenates were centrifuged at 600 x g for 5 min at 4°C, and the supernatants were centrifuged at 48,000 x g for 30 min. The pellets were resuspended in 10 vol of 50 mM Tris HCl (pH 7.4) and centrifuged at 48,000 x g for 30 min. Membranes (100 ,ug of protein) were incubated with 50 mM Tris-HCl (pH 7.4) containing 20 jig of bacitracin per ml and 1-3 nM 1251-CGP 23996 (specific activity, 1000 Ci/mmol; 1 Ci = 37 GBq) for 90 min at 25°C. For the photocrosslinking studies, the incubation mixture was centrifuged at 35,000 x g for 5 min at 4°C. The pellet was resuspended in 10 mM Hepes (pH 7.5), and this centrifugation step was repeated once. The 14) did not prevent the binding (Fig. 3) . Lack of complete blockade of the binding of the 60-kDa protein to the affinity column most likely was due to the degradation of the free [D-Trp8]SRIF by peptidases in the brain preparation.
To further demonstrate that the purified 60-kDa protein is the SRIF receptor, we covalently labeled the protein with 125I-CGP 23996 (Fig. 4) . For these studies, the purified receptor was incubated with a 10-fold excess of purified inhibitory GTP binding protein from brain (GO). This was done to enhance the affinity of the SRIF receptor for agonists. Previous studies (9) have shown that uncoupling of Go or G1 (inhibitory GTP-binding protein) from the SRIF receptor greatly reduces the affinity of the receptor for agonists. Since the purified SRIF receptor is associated with a relatively high concentration of phospholipids during and after its elution from the affinity column, it is possible that the SRIF receptor and G. had a reasonable opportunity to reassociate. 125I-CGP 23996 appeared to covalently label the purified SRIF receptor (Fig. 4) . In the absence of Go, 125I-CGP 23996 still labeled the receptor, although the amount of incorporation of the peptide was much less (not shown).
Furthermore, 125I-CGP 239% did not bind to purified G. by itself (not shown). The photoincorporation of 1 I-CGP 23996 into the purified SRIF receptor was blocked by 1 ,M [D-Trp8]SRIF (Fig. 4) . In contrast, 1 AuM somatostatin 28-(1-14) did not reduce the labeling of the receptor (Fig. 4) . Besides brain, SRIF receptors could be purified from the tumor cell line AtT-20, which expresses a high density of SRIF receptors (9) (Fig. 5) . The size of the protein purified from AtT-20 cells is similar to the size ofbrain SRIF receptors (Fig. 5) . Furthermore, the size of the protein purified from AtT-20 cells is similar to the size of the membrane-bound SRIF receptor covalently labeled with 1251I-CGP 23996 (Fig.   5) . In contrast to AtT-20 cells, no 60-kDa protein could be purified from an identical amount of CHO cells, which do not express '25I-CGP 23996 binding sites (Fig. 5 ).
DISCUSSION
A protein of 60 kDa was purified from rat brain by using an affinity The size of the brain SRIF receptor appears to be similar to the size of the SRIF receptor expressed in the anterior pituitary, a target site for SRIF's neuroendocrine actions. This is suggested from the present findings as well as the chemical crosslinking experiments of Thermos and Reisine (17) and Bruno and Berlowitz (24) , which showed that 125I-CGP 23996 labeled proteins of 60 kDa in rat pituitary membranes. In contrast, SRIF receptors in pancreatic acinar cells have a higher molecular mass than that of brain SRIF receptors. This was indicated from the photocrosslinking studies of Sakamoto et al. (25) , who proposed that the pancreatic acinar receptor has a molecular mass of 92 kDa. These findings suggest that heterogeneities in the structure of the SRIF receptor exist in different tissues.
Such molecular variations may be responsible for the functional differences in SRIF receptor subtypes. Subtypes of SRIF receptors were first proposed to exist in pancreatic islet cells. Mandarino et al. (26) and Brown et al. (27) observed that SRIF was more potent than its prohormone somatostatin 28 in blocking glucagon secretion from the pancreatic alpha cells. In contrast, somatostatin 28 was more potent than SRIF in inhibiting insulin secretion from pancreatic beta cells. Several investigators (1, 15) have suggested that distinct somatostatin 14 and somatostatin 28 receptors exist in brain. Recently, Wang et al. (28) showed that somatostatin 14 and somatostatin 28 induced opposite effects on the same voltage-dependent K+ current in cultures of rat embryonic cerebral cortical neurons, further suggesting that distinct somatostatin 14 and 28 receptors exist.
The molecular basis for the functional differences of SRIF receptors is unknown. Conceivably, the rather large differences in size between the brain and pancreatic acinar SRIF receptors could be due to different genes or mRNAs coding for the receptor subtypes. There is precedence for subtypes of neurotransmitter receptors being coded for by different genes or mRNAs. Bonner et al. (29) reported that four different genes code for muscarinic receptor subtypes. However, the rather subtle variations in structure of somatostatin 14 and 28 receptors proposed to exist by Thermos and Reisine (17) may be the result of the differential processing of a common receptor protein in various tissues.
The ability to purify the SRIF receptor should allow us to identify the structural basis of SRIF receptor heterogeneity. To this end, studies are in progress to sequence the SRIF receptor to develop antibodies and nucleic acid probes to investigate the genetic expression and processing of the SRIF receptor subtypes. Identification of these structural heterogeneities may explain the basis of the functional differences of SRIF receptor subtypes. Such information may be useful in understanding how SRIF and somatostatin 28 could induce different physiological actions as well as aid in the development of compounds that selectively interact with the different SRIF receptor subtypes. Such selective compounds could be therapeutically useful in the treatment of endocrine disorders such as diabetes and excessive growth hormone release.
